Wellmarker Bio(Dong-Hoon Jin, CEO) signed research agreement with KDDF(Hyun-sang Mook) on March 14, 2019 to promote successful development of WM-S1 which was first initiated in May, 2017. WM-S1 targets Cetuximab-resistant colon cancer patients and is backed by novel predictive biomarker.
Link: http://www.docdocdoc.co.kr/news/articleView.html?idxno=1066273
Link: http://www.docdocdoc.co.kr/news/articleView.html?idxno=1066273